Publication: PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
Date
Date
Date
Citations
Degenhardt, T., Fasching, P. A., Lüftner, D., Müller, V., Thomssen, C., Schem, C., Witzel, I., Decker, T., Tesch, H., Kümmel, S., Uleer, C., Wuerstlein, R., Hoffmann, O., Warm, M., Marschner, N., Schinköthe, T., Kates, R. E., Schumacher, J., Otremba, B., … PreCycle Investigators. (2023). PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant. Trials, 24(1), 338. https://doi.org/10.1186/s13063-023-07306-z
Abstract
Abstract
Abstract
Background Efficacy and quality of life (QoL) are key criteria for therapy selection in metastatic breast cancer (MBC). In hormone receptor positive (HR +) human epidermal growth factor receptor 2 negative (HER2 −) MBC, addition of targeted oral agents such as everolimus or a cycline-dependent kinase 4/6 (CDK 4/6) inhibitor (e.g., palbociclib, ribociclib, abemaciclib) to endocrine therapy substantially prolongs progression-free survival and in the case of a CDK 4/6i also overall survival. However, the prerequisite is a
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Degenhardt, Tom
- Fasching, Peter A
- Lüftner, Diana
- Müller, Volkmar
- Thomssen, Christoph
- Schem, Christian
- Witzel, Isabell
- Decker, Thomas
- Tesch, Hans
- Kümmel, Sherko
- Uleer, Christoph
- Wuerstlein, Rachel
- Hoffmann, Oliver
- Warm, Mathias
- Marschner, Norbert
- Schinköthe, Timo
- Kates, Ronald E
- Schumacher, Johannes
- Otremba, Burkhard
- Zaiss, Matthias
- Harbeck, Nadia
- Schmidt, Marcus
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Degenhardt, T., Fasching, P. A., Lüftner, D., Müller, V., Thomssen, C., Schem, C., Witzel, I., Decker, T., Tesch, H., Kümmel, S., Uleer, C., Wuerstlein, R., Hoffmann, O., Warm, M., Marschner, N., Schinköthe, T., Kates, R. E., Schumacher, J., Otremba, B., … PreCycle Investigators. (2023). PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant. Trials, 24(1), 338. https://doi.org/10.1186/s13063-023-07306-z
